CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and gene expression profiling (GEP) of purified BM CD1...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society for Clinical Investigation
2022-09-01
|
| Cyfres: | The Journal of Clinical Investigation |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1172/JCI159527 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
